A Case of Quadruple Viral Infections and Elevated Aminotransferase Activities

Abstract

A 40-year-old man with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) infection was referred for evaluation of abnormal liver enzyme activities. The patient was maintained on antiretroviral therapy for HIV as well as medication to suppress HBV and had previously undergone treatment for HCV with durable sustained virologic response. The patient was clinically well without any symptoms or evidence of liver decompensation. Laboratory findings were notable for aminotransferase activities in the 200 to 225 U/L range that had been persistent for several months. An extensive workup for the etiology of the aminotransferase elevation ensued. Imaging studies showed no evidence of biliary obstruction. Serology revealed negative autoantibodies, negative serum HCV-RNA, and low level HBV-DNA by polymerase chain reaction. Further testing revealed positive hepatitis delta virus (HDV) antibody and positive HDV RNA in the serum. A percutaneous liver biopsy was performed to further elucidate the cause of the elevated aminotransferase activities. Based on histology, serology, and clinical presentation, a diagnosis of chronic HDV infection was made. HDV infection should be considered in patients with known chronic viral hepatitis B with low viral load, who present with worsening liver function or elevation in aminotransferase activities.

Keywords

viral hepatitis - hepatitis D - human immunodeficiency virus

• References

• 1 Rizzetto M, Canese MG, Aricò S , et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18 (12) 997-1003
• 2 Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378 (9785) 73-85
• 3 Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis 2010; 28 (1) 133-138
• 4 Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7 (1) 31-40
• 5 Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine 1990; 8 (Suppl) S10-S14 , discussion S21–S23
• 6 Buitrago B, Hadler SC, Popper H , et al. Epidemiologic aspects of Santa Marta hepatitis over a 40-year period. Hepatology 1986; 6 (6) 1292-1296
• 7 Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res 1991; 364: 1-20
• 8 Kucirka LM, Farzadegan H, Feld JJ , et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010; 202 (6) 845-852
• 9 Shukla NB, Poles MA. Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus. Clin Liver Dis 2004; 8 (2) 445-460 , viii
• 10 Soriano V, Grint D, d'Arminio Monforte A , et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011; 25 (16) 1987-1992
• 11 Su CW, Huang YH, Huo TI , et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130 (6) 1625-1635
• 12 Sheng WH, Hung CC, Kao JH , et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44 (7) 988-995
• 13 Caredda F, d'Arminio Monforte A, Rossi E , et al. Prospective study of epidemic delta infection in drug addicts. Prog Clin Biol Res 1983; 143: 245-250
• 14 Smedile A, Farci P, Verme G , et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2 (8305) 945-947
• 15 Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int 2011; 31 (1) 7-21
• 16 Niro GA, Gioffreda D, Fontana R. Hepatitis delta virus infection: open issues. Dig Liver Dis 2011; 43 (Suppl. 01) S19-S24
• 17 Smedile A, Lavarini C, Crivelli O, Raimondo G, Fassone M, Rizzetto M. Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen: clinical significance in delta infection. J Med Virol 1982; 9 (2) 131-138
• 18 Negro F, Rizzetto M. Diagnosis of hepatitis delta virus infection. J Hepatol 1995; 22 (1, Suppl) 136-139
• 19 Coppola RC, Manconi PE, Piro R, Di Martino ML, Masia G. HCV, HIV, HBV and HDV infections in intravenous drug addicts. Eur J Epidemiol 1994; 10 (3) 279-283
• 20 Deterding K, Pothakamuri SV, Schlaphoff V , et al. Clearance of chronic HCV infection during acute delta hepatitis. Infection 2009; 37 (2) 159-162
• 21 Boyd A, Lacombe K, Miailhes P , et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010; 17 (1) 65-76
• 22 Arribas JR, González-García JJ, Lorenzo A , et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19 (13) 1361-1365
• 23 Rizzetto M, Hepatitis D. Hepatitis D: clinical features and therapy. Dig Dis 2010; 28 (1) 139-143
• 24 Wedemeyer H, Yurdaydìn C, Dalekos GN , et al; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364 (4) 322-331
• 25 Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011; 12 (12) CD006002
• 26 Samuel D, Zignego AL, Reynes M , et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21 (2) 333-339
• 27 Taniguchi M, Shakil AO, Vargas HE , et al. Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. Liver Transpl 2000; 6 (1) 92-96
• 28 Mederacke I, Filmann N, Yurdaydin C , et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol 2012; 56 (1) 115-122